Zynteglo gets the nod, and the hard work begins
Bluebird’s gene therapy is to be launched in the US priced $2.8m per patient, but can the company tread the cautious path to profitability?
Device approvals drop, but the FDA has a plan
Increased headcount should allow the FDA to up the number of approvals – but not quite yet.
